Sarepta Therapeutics, Inc.
SRPT
$20.55
$0.080.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -34.65% | -17.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -34.65% | -17.96% | |||
| Cost of Revenue | 3.56% | -60.82% | |||
| Gross Profit | -88.32% | 252.95% | |||
| SG&A Expenses | -33.36% | 3.19% | |||
| Depreciation & Amortization | 1.50% | 10.98% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.72% | -52.59% | |||
| Operating Income | -154.40% | 138.48% | |||
| Income Before Tax | -226.30% | 140.06% | |||
| Income Tax Expenses | 67.40% | -167.59% | |||
| Earnings from Continuing Operations | -191.39% | 144.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -191.39% | 144.00% | |||
| EBIT | -154.40% | 138.48% | |||
| EBITDA | -135.14% | 143.53% | |||
| EPS Basic | -189.36% | 143.71% | |||
| Normalized Basic EPS | -154.31% | 138.73% | |||
| EPS Diluted | -195.39% | 141.02% | |||
| Normalized Diluted EPS | -159.08% | 135.60% | |||
| Average Basic Shares Outstanding | 2.28% | 0.66% | |||
| Average Diluted Shares Outstanding | -5.99% | 9.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||